Paris-based Sofinnova Partners announced on November 16, 2026, that it raised €725 million ($815 million) for its largest crossover fund to date, Sofinnova Crossover II. The fund addresses a European scale-up financing gap by supporting roughly 15 late-stage drugmakers and medtech firms, including early capital deployments to CellCentric and Hemab Therapeutics. Sofinnova manages approximately €4 billion in total assets.
Sofinnova Crossover II fundraising and size
- ▪Sofinnova Crossover II is the largest crossover fund raised by Sofinnova Partners to date, bringing the firm's total assets under management to approximately €4 billion
- ▪Paris-based venture capital firm Sofinnova Partners announced it raised €725 million for its second crossover fund, Sofinnova Crossover II
Sofinnova Crossover II strategy and investments
- ▪Sofinnova Crossover II has already deployed capital into clinical-stage biotechnology companies CellCentric and Hemab Therapeutics
- ▪Sofinnova Crossover II plans to invest in approximately 15 late-stage drugmakers and medical device developers nearing product commercialization, primarily in Europe
Executives on European life sciences capital
- ▪Sofinnova Partners chairman Antoine Papiernik stated that the €725 million fund scale reflects European life sciences maturity and rising capital demand to reach global markets
- ▪Sofinnova Partners partner Kinam Hong stated that Europe faces a scale-up financing problem rather than an innovation problem for life sciences companies
Past successful Sofinnova biotech investments
- ▪Sofinnova Partners backed Verona Pharma, which brought a lung disease treatment to commercial market before being acquired by Merck & Co.
- ▪Sofinnova Partners partner Kinam Hong led an initial investment in immune drugmaker Abivax, which later reached a public market valuation of approximately $7 billion
Early-stage biotech investments
- ▪In 2025, Sofinnova Partners raised €650 million ($750 million) to support young therapeutics and medical technology developers
- ▪In 2026, Sofinnova Partners posted investments in early-stage biotech startups including Alethio Therapeutics, Bionyra, and T-Therapeutics
Biotechnology venture funding activity in 2026
- ▪According to an October 2026 report by investment firm William Blair, biotechnology venture capital firms raised over $13 billion in new funding during 2026
- ▪BioPharma Dive tracking data shows top sector investors completed more than 70 private funding rounds for clinical-stage biotechs in Phase 1 trials or later during 2026
Story comments
Loading comments…